Delayed antibiotic prescriptions
It is very uncertain whether NSAIDs changes delayed antibiotic prescriptions compared with paracetamol (very low certainty).
1 finding from 1 review
to 7 days
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events
It is very uncertain whether paracetamol changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Mean time to resolution of pain
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean pain score at various time points
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Reconsultations
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Delayed antibiotic prescriptions
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
hours
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression of DRa · people with type 2 diabetes
The intervention showed no clear difference in progression of DRa (moderate certainty).
1 finding from 1 review
Intervention not reported
Incidence of a reduction in visual acuity of 10 ETDR letters or more · people with type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Incidence of PDR · people with type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
Incidence of DMOa · people with type 2 diabetes
The intervention showed no clear difference in incidence of DMOa (moderate certainty).
1 finding from 1 review
Intervention not reported
Mean vision‐related quality of life · people with type 2 diabetes
The review found no eligible studies for this question.
1 finding from 1 review
Intervention not reported
SAEa · people with type 2 diabetes
The intervention leads to higher SAEa (high certainty).
1 finding from 1 review
Time to death from any cause Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors showed no clear difference in time to death from any cause Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review
Time to death from bladder cancer · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Time to progression · participants with advanced or metastatic muscle invasive bladder cancer
It is very uncertain whether immune checkpoint inhibitors changes time to disease progression Range of compared with any second‐line chemotherapy (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors may leads to lower discontinuation due to adverse events Range of compared with any second‐line chemotherapy (low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced or metastatic muscle invasive bladder cancer
1 finding from 1 review
Adverse events grade 3 to 5 Range of · participants with advanced or metastatic muscle invasive bladder cancer
Immune checkpoint inhibitors probably leads to lower adverse events grade 3 to 5 Range of compared with any first‐line chemotherapy (moderate certainty).
1 finding from 1 review